These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 19648052)

  • 1. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib.
    Broxterman HJ; Gotink KJ; Verheul HM
    Drug Resist Updat; 2009; 12(4-5):114-26. PubMed ID: 19648052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
    Wang W; Zhou J; Zhao L; Chen S
    Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.
    Sablin MP; Dreyer C; Colichi C; Bouattour M; Delbaldo C; Faivre S; Raymond E
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):1005-15. PubMed ID: 20636223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib in solid tumors.
    Gan HK; Seruga B; Knox JJ
    Expert Opin Investig Drugs; 2009 Jun; 18(6):821-34. PubMed ID: 19453268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines.
    Bender C; Ullrich A
    Int J Cancer; 2012 Jul; 131(2):E45-55. PubMed ID: 22020623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of multidrug resistant advanced alveolar soft part sarcoma with sunitinib.
    Ghose A; Tariq Z; Veltri S
    Am J Ther; 2012 Jan; 19(1):e56-8. PubMed ID: 20634674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.
    Wijdeven RH; Pang B; Assaraf YG; Neefjes J
    Drug Resist Updat; 2016 Sep; 28():65-81. PubMed ID: 27620955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
    Kancha RK; Grundler R; Peschel C; Duyster J
    Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib: from rational design to clinical efficacy.
    Chow LQ; Eckhardt SG
    J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents.
    Goard CA; Mather RG; Vinepal B; Clendening JW; Martirosyan A; Boutros PC; Sharom FJ; Penn LZ
    Int J Cancer; 2010 Dec; 127(12):2936-48. PubMed ID: 21351272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance.
    Maxwell SA; Mousavi-Fard S
    Exp Biol Med (Maywood); 2013 Sep; 238(9):971-90. PubMed ID: 23986223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of cell sensitivity to antitumor agents by targeting survival pathways.
    Perego P; Cossa G; Zuco V; Zunino F
    Biochem Pharmacol; 2010 Nov; 80(10):1459-65. PubMed ID: 20688050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming multidrug resistance (MDR) in cancer in vitro and in vivo by a quinoline derivative.
    Ganguly A; Banerjee K; Chakraborty P; Das S; Sarkar A; Hazra A; Banerjee M; Maity A; Chatterjee M; Mondal NB; Choudhuri SK
    Biomed Pharmacother; 2011 Sep; 65(6):387-94. PubMed ID: 21715129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
    Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
    Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
    Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
    Mena AC; Pulido EG; Guillén-Ponce C
    Anticancer Drugs; 2010 Jan; 21 Suppl 1():S3-11. PubMed ID: 20110785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular cytogenetic characterization of doxorubicin-resistant neuroblastoma cell lines: evidence that acquired multidrug resistance results from a unique large amplification of the 7q21 region.
    Flahaut M; Mühlethaler-Mottet A; Martinet D; Fattet S; Bourloud KB; Auderset K; Meier R; Schmutz NB; Delattre O; Joseph JM; Gross N
    Genes Chromosomes Cancer; 2006 May; 45(5):495-508. PubMed ID: 16450357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance in chemotherapy for breast cancer.
    Saeki T; Tsuruo T; Sato W; Nishikawsa K
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.